ACADIA Pharmaceuticals Inc. (ACAD:NASDAQ) closed at $20.31 on October 22, 2026, up 0.59% on the day. The stock trades 34.4% below its 52-week high of $30.96 and 10.4% above its 52-week low of $18.39. Over the past year, it lost 6.5%. ACADIA Pharmaceuticals Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 22, 2025, ACAD closed higher on 123 days (49%). Its best day was November 11, 2025 (+6.85%) and its worst was September 24, 2026 (-12.78%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 1 time.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer's disease psychosis. The company has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Find more stocks like ACAD with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.